ArticleBMC research notes2025
Magnitude and factors associated with virological failure among adults on first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia: a retrospective chart review.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst-line antiretroviral therapy failure reduces the benefits of the antiretroviral therapy (ART) program and could lead to regimen change to a more expensive second-line ART. To identify ART failure, routine viral load monitoring is recommended as the gold standard and has been implemented in Ethiopia since 2017. However, evidence regarding the virological failure of the first-line ART is limited in the study setting, Dire Dawa Ethiopia.
objectiveThis study aimed to determine the magnitude and factors associated with virological treatment failure among adults on first-line ART follow-up in Dire Dawa between January 2017 and December 2019.
methodsA retrospective chart review was conducted among 272 randomly selected adults on first-line ART follow-up, between January 2017 to December 2019. Data were collected from patients’ medical records, entered into epi data version 3.02 and exported to Stata version 15 software for analysis. A bivariable and multivariable binary logistic regression model was used to identify factors associated with virological first-line ART failure. The goodness of fit of the model was assessed using the Hosmer–Lemeshow test. All statistical tests are declared significant at a P-value of < 0.05.
resultsA total of 257 ART patients’ records were included for final analysis. The magnitude of first-line ART virological failure was 11.28% (95% CI 7.69, 15.80). Baseline undernutritional status (AOR = 3.72: 1.05, 13.14), serostatus nondisclosure (AOR = 4.45: 1.34, 14.79), early (≤ 30 days) ART initiation (AOR = 0.235: 0.064, 0.859), history of missed any daily ART dose (AOR = 3.16: 1.01, 9.89) and dolutegravir-based regimen (AOR = 0.28: 0. 09, 0.90) were significantly associated with virological failure of first-line ART.
conclusionThe magnitude of virological first-line ART failure in this study was relatively high. Virological first-line ART failure was significantly associated with baseline BMI, HIV serostatus disclosure, duration of ART initiation after HIV diagnosis, history of missed ART doses, and substitution of DTG-based ART first-line regimens. To avoid treatment failure, it is crucial to disclose one's serostatus, encourage adherence initiatives, and early initiation of ART preferably a dolutegravir-based regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.